Since its inception nearly five decades ago, ELISA immunoassays are now a gold standard for diagnosing and evaluating drug studies. Immunoassay services rely on ELISA method development to quantify different analytes such as hormones, peptides, and proteins in complex biological matrices. ELISA assays immobilize the analyte of interest in a microplate using specific antibodies specific to the molecule. Due to its versatility and specification, ELISA has remained a popular tool in biomedical and clinical research. The current article discusses the role of ELISA services in drug discovery and development.
ELISA assay labs: a vital tool for accelerating drug development
ELISA assay labs, a vital tool for accelerating drug development is Immunoassay services heavily rely on ELISA assays in discovery and development studies. ELISA is crucial for assessing the efficacy of therapeutic drugs against inflammatory cytokines. By measuring cytokine levels in biological samples, researchers can evaluate the capacities of antibody clones in blocking the production of cytokines such as TNF-alpha and IL-8.
ELISA assays can reliably evaluate the PK properties of therapeutic antibodies. In pharmacokinetic ELISA studies, researchers can determine antibodies in blood samples at various time points. These evaluations help measure drug half-life and provide data that can guide researchers in selecting the most stable antibody clones.
Different ELISA formats have multiple research applications, including CRISPR-knockout studies, for example, p53 gene knockout experiments involving tumor suppression. The P53 gene encodes a tumor suppressor. ELISA assays can evaluate decreased p53 levels in knockout cells, demonstrating its application in gaining gene function insights and the ability to develop targeted therapies.
ELISA immunoassays have several advantages over other immunoassay formats. ELISA assays are highly versatile. Similarly, they are highly specific and sensitive. They provide different readout methods, such as colorimetric detection. Besides, newer detection readouts, such as luminescent and fluorescent detection, offer better dynamic range and sensitivity. Highly sensitive ELISA can detect molecules present in low abundance.
Specificity is a vital feature of ELISA assays. This attribute allows ELISA to distinguish between closely related molecules. However, the choice of antibody dictates the specificity of the ELISA assay. Hence, the correct antibodies ensure the detection of target analytes and the minimization of cross-reactivity with similar matrix components.
Additionally, ELISA assays are simple to perform. ELISA assays only need samples, pipettes, plates, and plate readers. However, despite a few requirements, ELISA assays can deliver a broad range of assays. Moreover, ELISA assays are automation-friendly, making them even more streamlined and accessible.
Automation in ELISA protocols upgrades several manual steps. However, the extent of method automation depends on the throughput needs of an experiment. Scientists use automated liquid handlers for preparing samples and adding reagents. On the other hand, robotic arms can transfer plates among sections of an experimental system. Combining automated liquid handlers with robotic arms allows researchers to automate the systems for adding reagents or carrying plates and focus more on experimental discussions.
Despite innovations in detection technology, ELISA assays remain a benchmark in diagnosis and detection. Moreover, ELISA had a significant role in expanding an understanding of the COVID-19 disease mechanism by detecting antibodies against the nucleocapsid antigen, spike protein, and other viral proteins.
Must Read: Multiplexed ELISA for Biomarker Discovery: Uncovering New Insights in Cancer Research
